Silo Pharma, Inc. SILO
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Silo Pharma, Inc. (SILO) is a healthcare company listed in the US with a market value of about $4M. In the twelve months to September 30, 2026 it had revenue of $36052 and net income of -$4M, a net margin of -10319.0%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is financial health (4/5); the weakest is shareholder returns (0/5).
Key numbers: a P/E of 0.3, 5-year revenue growth of 12% a year, a 5-year average ROIC of -47%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.
About Silo Pharma
Silo Pharma is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $40569 in 2019 to $72102 in 2025, growth of about 10.1% a year. It was profitable in 2 of the last 10 years in our data. Its share count rose by 267% over three years (dilution for shareholders). It spends 2997% of revenue on research and development.
Score: 1.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36052 | $72102 | $72102 | $72102 | $72102 | — | $40923 | $40569 | — | — | — |
| Net income | -$4M | -$4M | -$4M | -$4M | -$4M | $4M | -$3M | -$1M | -$969463 | $356536 | -$39446 |
| Free cash flow | — | — | — | — | — | — | — | — | — | — | -$21473 |
| EPS (diluted) | $5.88 | $-0.50 | $-1.19 | $-1.20 | $-1.71 | $2.00 | $-2.50 | $-2.00 | $-1.00 | $0.50 | $0.00 |
| Net margin | -10319.0% | -5863.5% | -6092.6% | -5132.6% | -5420.9% | — | -7422.5% | -2497.7% | — | — | — |
| ROIC | — | -53.6% | -73.8% | -49.3% | -27.7% | -30.1% | -133.8% | -1885.5% | -115.2% | -32.2% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Silo Pharma’s P/E ratio?
About 0.3, based on the last twelve months of diluted earnings per share.
Is Silo Pharma stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Silo Pharma pay a dividend?
Not currently.
Is Silo Pharma a good stock to buy?
We do not give buy or sell advice. Silo Pharma scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.